NCE Discovery

poziotinib (pan-HER)
  • Most effective pan-HER inhibitor
  • Effective for EGFR mutant and HER2 positive/mutant driven solid tumors
  • Potent inhibition of EGFR and HER2 exon 20 mutations
belvarafenib (pan-RAF)
  • Potent pan-RAF inhibitor
  • Effective anti-tumor activities in RAF and RAS mutant driven cancers
  • Potent inhibitor of FMS-like tyrosine kinase 3 (FLT3) and FLT3 mutants including tyrosine kinase domain.
  • Effective therapy for the FLT3 mutants driven cancers, such as AML
  • Effective Bruton’s tyrosine kinase (BTK) inhibitor
  • Potent inhibition of BTK signaling in B cell such as p-BTK and p-PLCγ